| Target Price consensus revisions : last 18 months |
|
|
|
| Evolution of the average Target Price on GILEAD SCIENCES, INC. |
|
|
|
Financial data source
© 2020 S&P Global Market Intelligence
|
|
|
Gilead Sciences : cuts 2020 sales outlook as COVID-19 drug remdesivir falls short |
| Mean consensus |
OUTPERFORM |
| Number of Analysts |
30 |
| Average target price |
74,21 $ |
| Last Close Price |
58,15 $ |
| Spread / Highest target |
80,6% |
| Spread / Average Target |
27,6% |
| Spread / Lowest Target |
-0,26% |
Consensus revision (last 18 months)
|
Canada
Deutschland
France
Schweiz (DE)
United Kingdom
Report
